Welcome to our dedicated page for Hookipa Pharma SEC filings (Ticker: HOOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HOOKIPA Pharma Inc. filings document public-company status changes for its common stock, governance actions, and material events. Form 25 records the voluntary withdrawal of the common stock from Nasdaq listing and Section 12(b) registration, while Form 15 records termination or suspension provisions under the Exchange Act for the same security class.
The filing record also includes 8-K disclosure on a special stockholder meeting, proxy-referenced vote matters, registered security details, and corporate-status disclosures associated with asset-sale and dissolution-related proposals.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) has called a virtual special meeting for 10:00 a.m. ET on July 29, 2025 to seek shareholder approval for three critical proposals:
- Asset Sale (Proposal 1): Sale of all assets related to the HB-400 (Hepatitis B) and HB-500 (HIV) programs, including IP and know-how, to long-time collaborator and 5%+ shareholder Gilead Sciences for up to $10 million cash ( $3 million at closing plus up to $7 million in three post-closing transfer-plan tranches).
- Dissolution (Proposal 2): Liquidation of the company pursuant to a Plan of Dissolution, conditional upon successful closing of the Asset Sale.
- Adjournment (Proposal 3): Authority to adjourn the meeting if additional proxy solicitation is required.
The Board unanimously recommends voting “FOR” all proposals.
Key financial terms
- Estimated net proceeds from the transaction: $7.6 million after taxes and expenses, assuming full $10 million consideration is earned.
- Board projects liquidating distributions of approximately $1.28 – $1.72 per common and Class A share (based on 12.2 million diluted shares) but no earlier than three years after filing the Certificate of Dissolution.
- If the Transfer Plan phases are disputed, related cash installments may be delayed or forfeited, and the company cannot file its dissolution certificate until all phases are accepted or waived.
- No appraisal or dissenters’ rights apply.
Strategic rationale
- Limited cash, no marketed products, rising public-company costs and historically low trading liquidity led the Board to pursue a sale after a year-long strategic review that included but ultimately rejected an alternative transaction with Poolbeg Pharma.
- Transaction allows monetisation of non-core infectious-disease programs while providing shareholders an exit path.
Process & governance
- Majority of outstanding common shares (≈4.9 million) must vote “FOR” to pass Proposals 1 and 2.
- Executive officers and directors will receive accelerated vesting of 178,570 RSUs and 13,264 options upon closing.
- Failure to approve the Dissolution does not block the Asset Sale, but would leave HOOK with no active programs or clear strategy.
Timeline
- Closing targeted as soon as regulatory clearance (Austrian FDI filing) and shareholder approval obtained, but outside deadline is Nov 21 2025.
- Transfer books will close on the “Final Record Date” when the Certificate of Dissolution is filed; shares are expected to be delisted from Nasdaq shortly after the special meeting.